利索-全球专利检索

  1. 登录
  2. 注册
发明公开
CN105250999A 用于治疗神经退行性变疾病的α-突出核蛋白和其疫苗的模拟表位 有权 转让

用于治疗神经退行性变疾病的α-突出核蛋白和其疫苗的模拟表位
摘要：
本发明涉及使用至少一种包含氨基酸序列(X1)nX2X3PVX4X5X6(X7)m(式1)的化合物，其中X1是任何氨基酸残基，X2是选自下组的氨基酸残基：天冬氨酸(D)和谷氨酸(E)，X3是任何氨基酸残基，X4是任何氨基酸残基，X5是选自下组的氨基酸残基：脯氨酸(P)和丙氨酸(A)，X6是选自下组的氨基酸残基：天冬氨酸(D)和谷氨酸(E)，X7是任何氨基酸残基，n和m，彼此独立，是0或大于0的整数，且其中式I的氨基酸序列并不包括α-突触核蛋白具有氨基酸序列DMPVDPDN的8聚体多肽片段，或并不与其等同，所述化合物具有对针对包含氨基酸序列DMPVDPDN的α-突触核蛋白表位具有特异性的抗体的结合能力，以供产生供预防和/或治疗突触核蛋白病的医药。
摘要（英）：

The present invention relates to the use of at least one compound comprising the amino acid sequence: (X1)nX2X3PVX4X5X6(X7)m (Formula I), wherein X1 is any amino acid residue, X2 is an amino acid residue selected from the group consist ing of aspartic acid (D) and glutamic acid (E), X3 is any amino acid residue, X4 is any amino acid residue, X5 is an amino acid residue selected from the group consisting of proline (P) and alanine (A), X6 is an amino acid residue selected from the group consisting of aspartic acid (D) and glutamic acid (E), X7 is any amino acid residue, n and m, independently, are 0 or an integer of more than 0, and wherein the amino acid sequence according to Formula I is not identical with, or does not comprise the 8-mer polypeptide fragment of alpha-synuclein having the amino acid sequence DMPVDPDN, said compound having a binding capacity to an antibody which is specific for an epitope of alpha-synuclein comprising the amino acid sequence DMPVDPDN for producing a medicament for preventing and/or treating synucleinopathies.

公开/授权文献
0/0